Jaguar Health Inc (JAGX) Q2 2024 Earnings Call Highlights: Revenue Growth Amidst Financial ...

GuruFocus.com10-10

Net Revenue Q2 2024: Approximately $2.72 million, a 16% increase from Q1 2024 ($2.35 million) and a 2% increase from Q2 2023 ($2.67 million). Release Date: August 13, 2024 For the complete transcript...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2474786924?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/HSRtE5lfo.WFHb2jT.4pyQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/22208671de4765ab8c52a54e40e7b192","is_english":true,"pubTime":"2024-10-10 06:16","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2474786924","market":"us","top_or_hot":-1,"title":"Jaguar Health Inc (JAGX) Q2 2024 Earnings Call Highlights: Revenue Growth Amidst Financial ...","media":"GuruFocus.com","content":"<div>\n<p>Net Revenue Q2 2024: Approximately $2.72 million, a 16% increase from Q1 2024 ($2.35 million) and a 2% increase from Q2 2023 ($2.67 million).\n\nRelease Date: August 13, 2024\nFor the complete transcript...</p>\n\n<a href=\"https://finance.yahoo.com/news/jaguar-health-inc-jagx-q2-221627250.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jaguar Health Inc (JAGX) Q2 2024 Earnings Call Highlights: Revenue Growth Amidst Financial ...</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJaguar Health Inc (JAGX) Q2 2024 Earnings Call Highlights: Revenue Growth Amidst Financial ...\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-10 06:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/jaguar-health-inc-jagx-q2-221627250.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Net Revenue Q2 2024: Approximately $2.72 million, a 16% increase from Q1 2024 ($2.35 million) and a 2% increase from Q2 2023 ($2.67 million).\n\nRelease Date: August 13, 2024\nFor the complete transcript...</p>\n\n<a href=\"https://finance.yahoo.com/news/jaguar-health-inc-jagx-q2-221627250.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JAGX","symbol_name":"Jaguar Animal Health, Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/jaguar-health-inc-jagx-q2-221627250.html","article_id":"2474786924","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/HSRtE5lfo.WFHb2jT.4pyQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/22208671de4765ab8c52a54e40e7b192"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2474786924","pubTimestamp":1728512187,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Net Revenue Q2 2024: Approximately $2.72 million, a 16% increase from Q1 2024  and a 2% increase from Q2 2023 .For the complete transcript of the earnings call, please refer to the full earnings call transcript.Jaguar Health Inc  reported a 16% increase in net revenue for Q2 2024 compared to Q1 2024, indicating positive sales momentum.The company observed clinically meaningful results in subgroups of breast and lung cancer patients in their Phase 3 OnTarget trial, showcasing potential for crofelemer in cancer therapy-related diarrhea.Despite revenue growth, Jaguar Health Inc  reported a net loss attributable to common shareholders of $9.5 million for Q2 2024, indicating ongoing financial challenges.The OnTarget trial results, while promising, are based on small sample sizes, which may limit the statistical significance and require further validation.Jaguar Health Inc  continues to experience operational losses, with a $7.2 million loss from operations in Q2 2024, highlighting the need ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"JAGX":"Jaguar Animal Health, Inc."},"translate_title":"Jaguar Health Inc(JAGX)2024年第二季度收益看涨期权亮点：财务状况下的收入增长...","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JAGX":1},"content_text":"Net Revenue Q2 2024: Approximately $2.72 million, a 16% increase from Q1 2024 ($2.35 million) and a 2% increase from Q2 2023 ($2.67 million).\n\nRelease Date: August 13, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nJaguar Health Inc (NASDAQ:JAGX) reported a 16% increase in net revenue for Q2 2024 compared to Q1 2024, indicating positive sales momentum.\nThe company observed clinically meaningful results in subgroups of breast and lung cancer patients in their Phase 3 OnTarget trial, showcasing potential for crofelemer in cancer therapy-related diarrhea.\nCrofelemer has received orphan drug designation in both the United States and EU for rare disease indications, which could provide market exclusivity and regulatory advantages.\nThe company is preparing for the commercial launch of Gelclair, an FDA-approved product for oral mucositis, in October 2024, expanding their product portfolio.\nJaguar Health Inc (NASDAQ:JAGX) is actively pursuing international clinical trials and collaborations, such as the investigator-initiated studies in the MENA region, enhancing their global research footprint.\n\n Negative Points \n\nDespite revenue growth, Jaguar Health Inc (NASDAQ:JAGX) reported a net loss attributable to common shareholders of $9.5 million for Q2 2024, indicating ongoing financial challenges.\nThe OnTarget trial results, while promising, are based on small sample sizes, which may limit the statistical significance and require further validation.\nThe company faces complex data analysis challenges from the OnTarget trial, which could delay regulatory submissions and potential FDA approval.\nJaguar Health Inc (NASDAQ:JAGX) continues to experience operational losses, with a $7.2 million loss from operations in Q2 2024, highlighting the need for improved cost management.\nThe companys reliance on non-GAAP financial measures may obscure the full picture of their financial health, potentially complicating investor assessments.\n\n Q & A Highlights \n\nWarning! GuruFocus has detected 7 Warning Signs with JAGX.\n\nQ: Can you explain the plan with the responder analysis in the OnTarget trial and the goal of meeting with the FDA? A: The plan is to continue with the responder analysis to show the robustness of our findings, particularly in breast and lung cancer patients. We will discuss these findings with clinical and regulatory key opinion leaders and evaluate other gastrointestinal endpoints. A briefing document will be prepared for the FDA, including obligatory pre-specified statistical analysis and additional exploratory responder analysis. This will help assess the benefit/risk ratio of crofelemer for cancer therapy-related diarrhea, especially in breast and lung cancer patients. - Pravin Chaturvedi, Chief Scientific Officer\nQ: How does the OnTarget trial add to the clinical evidence for crofelemer in cancer patients? A: The OnTarget trial provided additional evidence of crofelemer's benefits, not only in breast cancer patients but also in lung cancer patients receiving targeted therapy. This trial was designed to be inclusive of various solid tumors, allowing us to identify benefits across different cancer types. - Pravin Chaturvedi, Chief Scientific Officer\nQ: What are the targeted rare disease indications for crofelemer, and how does it work in these patient populations? A: Crofelemer targets rare diseases like short bowel syndrome with intestinal failure (SBS-IF) and microvillus inclusion disease (MVID). It acts locally in the gut to reduce chloride secretion and accompanying fluid accumulation, thus reducing diarrhea. This is crucial for SBS-IF patients who rely on total parenteral nutrition and MVID patients who lack a brush border membrane in their intestines. - Pravin Chaturvedi, Chief Scientific Officer\nQ: What is the significance of the Gelclair launch for Jaguar Health? A: The Gelclair launch is significant as it addresses oral mucositis, a common and debilitating side effect of cancer treatment. Gelclair provides soothing pain relief without numbing, improving patients' ability to eat, drink, and speak. The launch will focus on head and neck cancer patients, who are particularly affected by oral mucositis. - Cathy Collis, Senior Vice President, Growth Strategy\nQ: Can you provide a financial overview for the second quarter of 2024? A: The combined revenue for Q2 2024 was approximately $2.72 million, a 16% increase from Q1 2024 and a 2% increase from Q2 2023. Mytesi prescription volume increased by 5.2% compared to Q1 2024. The net loss attributable to common shareholders decreased by $2.6 million compared to the same period in 2023. - Carol Lizak, Chief Financial Officer\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2474786924"}